Status:
COMPLETED
Effects of Moringa Oleifera on hsCRP and Hgba1c Level of Patients in Ospital ng Maynila Medical Center Diabetic Clinic
Lead Sponsor:
Ospital ng Maynila Medical Center
Conditions:
Diabetes
Eligibility:
All Genders
19-75 years
Phase:
PHASE1
Brief Summary
Current evidence supports a central role of inflammation in the pathogenesis of atherosclerosis and diabetes \[57-60\]. Diabetes Mellitus type 2 is an inflammatory atherothrombotic condition associate...
Detailed Description
We performed a prospective cohort study of adult diabetics who were given 12-weeks supplementation of Moringa oleifera. Plasma hsCRP and serum HgbA1c were compared before and after treatment with M. o...
Eligibility Criteria
Inclusion
- Male or female participants aged between 19 and 65 years of age.
- They were diagnosed by the Internal Medicine resident or other physician as having Diabetes Mellitus using the following criteria stated by American Diabetes Association (ADA)
- Participants should be willing to have their blood extracted for hsCRP and Hgba1c measurement before and after 12 weeks supplementation of M. oleifera.
- Participants have available treatment partner.
- Subjects who have been diagnosed with other diseases such as asthma, stroke, or hypertension was included in the trial provided since they are already medically stable and that these diseases are not listed as part of the exclusion criteria.
Exclusion
- Subjects who are suspected to have psychiatric disorders, mentally challenged, or confirmed to be pregnant
- Subjects who are not medically stable or those confirmed to be afflicted with communicable or life threatening diseases such as but not limited to the following:
- ongoing infection (Pulmonary Tuberculosis, DM foot infection, cellulitis, pneumonia, Urinary Tract Infections, ear infections or dental/gum Infections)
- decompensated heart failure ( CHF III-IV)
- chronic liver disease in decompensated state
- stroke in evolution,
- acute coronary syndrome within 6 months,
- systemic or pulmonary inflammatory condition (including rheumatoid arthritis, systemic lupus erythematosus,
- chronic obstructive pulmonary disease in exacerbation,
- bronchial asthma in exacerbation, history of renal or other organ transplant and/or
- immunocompromised state
- Subjects with anemia (hemoglobin value of less than 13.0 g/dl in males; 12.0 g/dl in females)
- Subjects with undergoing Moringa oleifera, fish oil or any vitamins or multivitamins supplementation within the past 8 weeks are excluded in the study.
- Subjects with the use of estrogen/progesterone hormone. Subjects with plan or anticipated by their physicians to be initiated with renal replacement therapy (dialysis) during the study.
- Subjects who are pregnant or plan to be pregnant.
- Subjects with known or suspected allergy to M. oleifera or any other component to the drug preparation.
Key Trial Info
Start Date :
August 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2014
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT02308683
Start Date
August 1 2014
End Date
November 1 2014
Last Update
December 4 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.